Recent advances in allergen immunotherapy

Area of Science:

• Immunology
• Allergy Research
• Therapeutic Development

Background:

• Allergen immunotherapy (AIT) is the sole disease-modifying treatment for immunoglobulin (Ig) E-mediated allergic conditions like rhinitis, asthma, food allergies, and atopic dermatitis.
• Advances in understanding immunological tolerance mechanisms are crucial for improving AIT.

Purpose of the Study:

• To provide a comprehensive review of recent advancements in AIT.
• To focus on immunological mechanisms, novel vaccines, biomarkers, clinical outcomes, and combination strategies.

Main Methods:

• Review of current literature on AIT.
• Analysis of immunological mechanisms involving regulatory T/B cells, innate lymphoid cells, and blocking antibodies.
• Evaluation of novel vaccine technologies and biomarkers for AIT response.

Main Results:

• Established roles of regulatory cells and antibodies in inducing tolerance.
• Development of novel allergen vaccines (recombinant, VLP conjugates, peptide vaccines) for enhanced safety and efficacy.
• Demonstrated clinical efficacy of AIT in asthma, allergic rhinitis, and atopic dermatitis, with growing evidence in food allergies.
• Promising results from combining AIT with biologics (anti-IgE, anti-IL-4/IL-4R) for severe asthma.

Conclusions:

• AIT is a key therapy for allergic diseases, with ongoing innovation in vaccines and combination strategies.
• Challenges in patient selection, treatment duration, and standardization persist.
• Future research should focus on predictive biomarkers, shorter treatment courses, and synergistic biologic-AIT approaches.